Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10283044" target="_blank" >RIV/00216208:11110/14:10283044 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216224:14110/14:00075327 RIV/00216208:11130/14:10283044 RIV/61989592:15110/14:33149138 RIV/00064203:_____/14:10283044 RIV/00064190:_____/14:#0000837
Výsledek na webu
<a href="http://dx.doi.org/10.1186/1471-230X-14-53" target="_blank" >http://dx.doi.org/10.1186/1471-230X-14-53</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1186/1471-230X-14-53" target="_blank" >10.1186/1471-230X-14-53</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry
Popis výsledku v původním jazyce
Background: Patients aged 65 years and older represent the majority of patients with metastatic colorectal cancer (mCRC). However, this patient population is often underrepresented in clinical trials and probably undertreated in the clinical practice. Methods: We have analysed the outcomes of 3,187 mCRC patients treated with first-line bevacizumab based on data from the Czech national registry of mCRC patients aiming to compare the treatment efficacy and safety according to the age categories. Results:In total, 2,126 (66.7%), 932 (29.2%), and 129 (4.0%) patients were aged < 65 years, 65 to 75 years, and 75+ years, respectively. Median progression-free survival (PFS) was 11.4, 11.3, and 11.8 months for patients aged < 65 years, 65 to 75 years, and 75+years, respectively (p = 0.94). Median overall survival (OS) was 26.9, 27.5, and 25.1 months for patients aged < 65 years, 65 to 75 years, and 75+ years, respectively (p = 0.73). Using multivariable Cox model for both PFS and OS, the pati
Název v anglickém jazyce
Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry
Popis výsledku anglicky
Background: Patients aged 65 years and older represent the majority of patients with metastatic colorectal cancer (mCRC). However, this patient population is often underrepresented in clinical trials and probably undertreated in the clinical practice. Methods: We have analysed the outcomes of 3,187 mCRC patients treated with first-line bevacizumab based on data from the Czech national registry of mCRC patients aiming to compare the treatment efficacy and safety according to the age categories. Results:In total, 2,126 (66.7%), 932 (29.2%), and 129 (4.0%) patients were aged < 65 years, 65 to 75 years, and 75+ years, respectively. Median progression-free survival (PFS) was 11.4, 11.3, and 11.8 months for patients aged < 65 years, 65 to 75 years, and 75+years, respectively (p = 0.94). Median overall survival (OS) was 26.9, 27.5, and 25.1 months for patients aged < 65 years, 65 to 75 years, and 75+ years, respectively (p = 0.73). Using multivariable Cox model for both PFS and OS, the pati
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Ostatní
Rok uplatnění
2014
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
BMC Gastroenterology
ISSN
1471-230X
e-ISSN
—
Svazek periodika
14
Číslo periodika v rámci svazku
March
Stát vydavatele periodika
GB - Spojené království Velké Británie a Severního Irska
Počet stran výsledku
8
Strana od-do
—
Kód UT WoS článku
000334417600002
EID výsledku v databázi Scopus
—